Adrenarche refers to a maturational increase in the secretion of adrenal androgen precursors, mainly dehydroepiandrosterone (DHEA) and its sulfate (DHEAS). In premature adrenarche (PA), clinical signs of androgen action appear before the age of 8/9 years in girls/boys, concurrently with the circulating DHEA(S) concentrations above the usually low prepubertal level. The most pronounced sign of PA is the appearance of pubic/axillary hair, but also other signs of androgen effect (adult type body odor, acne/comedones, greasy hair, accelerated statural growth) are important to recognize. PA children are often overweight and taller than their peers, and the higher prevalence of PA in girls than in boys is probably explained by higher female adiposity and peripheral DHEA(S) conversion to active androgens. PA diagnosis requires exclusion of other causes of androgen excess: congenital adrenal hyperplasia, androgen-producing tumors, precocious puberty, and exogenous source of androgens. PA has been linked with unfavorable metabolic features including hyperinsulinism, dyslipidemia, and later-appearing ovarian hyperandrogenism. Although this common condition is usually benign, PA children with additional risk factors including obesity should be followed up, with the focus on weight and lifestyle. Long-term follow-up studies are warranted to clarify if the metabolic changes detected in PA children persist until adulthood.

Adrenarche refers to a maturational increase in the secretion of adrenal androgen precursors (AAPs) in mid-childhood, occurring typically at around 5-8 years of age. The main AAPs are dehydroepiandrosterone (DHEA) and its sulfate (DHEAS). The clinical signs of adrenal androgen action are normally seen after the age of 8 and 9 years in girls and boys, respectively. Premature adrenarche (PA) refers to the presentation of androgenic signs - appearance of pubic and axillary hair, adult type body odor, oily hair, acne or comedones - before the age of 8 years in girls or 9 years in boys in the absence of central puberty, steroidogenic enzyme defects, androgen-producing tumors, or exogenous source of androgens, concurrently with circulating AAP concentrations above the usual low prepubertal level [1,2,3,4,5]. The first descriptions of the phenomenon were published in early 1950s, when early development of pubic hair (premature pubarche, PP) in otherwise healthy prepubertal girls was reported [6]. These historical reasons probably explain why PP is still often erroneously used as a synonym for PA although only about half of the children with PA have pubic or axillary hair at the time of PA diagnosis, at least in the Northern European Caucasian population [2,3,5].

Until late 1990s, PA was regarded as a benign variant of pubertal development with no need for special follow-up or treatment. Thereafter, several studies have connected PA with components of the metabolic syndrome (MBS) [7,8,9,10,11,12,13] and some with various other disturbances including functional ovarian hyperandrogenism (FOH) [14,15,16]. The extended Barker hypothesis of intrauterine programming of metabolism has been suggested also in PA [16]. While a growing body of evidence suggests a connection of PA with metabolic disturbances at the prepubertal age, solid evidence for the persistence of the observed metabolic changes through pubertal development until adulthood is lacking.

The mechanisms of PA remain unclear, but the adipose tissue seems to play a role in the presumably multifactorial etiology. No genome-wide association studies on timing of adrenarche exist, but several candidate genes have been studied with only weak associations found [reviewed in [4], [5]]. In this mini review, we discuss the definitions, mechanisms and clinical presentation of PA, and the connection between PA and various metabolic disturbances. The recommendations for management and follow-up of children with PA are also discussed.

Adrenarche refers to a maturational increase in the adrenal production of androgen precursors in mid-childhood. In the adrenal cortex, two main changes are needed for adrenarche: the cortical zone specialized for producing androgens (zona reticularis, ZR) has to be formed, and the expression of the steroidogenic enzymes and cofactors favoring AAP production has to be appropriate [17,18,19]. The mid-childhood increase in AAP production can be called ‘biochemical adrenarche', whereas the appearance of androgenic signs due to increasing adrenal androgen secretion stands for ‘clinical adrenarche'. A serum DHEAS level exceeding 1 µmol/l (≈40 µg/dl) has often been regarded as a biochemical hallmark of adrenarche [3,5]. The androgenic signs of adrenarche include adult-type body odor, greasy hair, acne and/or comedones, and axillary and/or pubic hair. The appearance of pubic hair is called pubarche. PA refers to an earlier than normal appearance of clinical signs of adrenarche [1,2,3,4,5]. As the appearance of pubic hair is often considered the most striking of these clinical signs, PP has often been used as a synonym for clinical PA. Analogically with the phrase ‘biochemical adrenarche', PA could also be understood as premature biochemical adrenarche, defined by increased circulating AAP levels or urinary adrenal androgen metabolites. As the increase in adrenal androgen production in childhood is gradual and usually relatively slow, it would be difficult to define valid serum or urinary AAP (metabolite) threshold levels for biochemical adrenarche.

The term ‘exaggerated adrenarche' has also been used in connection with PA [20,21,22]. This term usually refers to PA with androgen levels higher than expected for the Tanner stage of pubic hair, but some authors have used it as a synonym for PA [22]. According to Likitmaskul et al. [20], circulating DHEAS concentrations exceeding the late-pubertal reference values or 6 μmol/l (≈222 µg/dl) would indicate exaggerated adrenarche. Other terms that have been used in connection with PA include amplified [23] and pronounced adrenarche [16]. Due to the variable and confusing use of the terms exaggerated, pronounced and amplified adrenarche, we preferably use just the term PA for this condition [5].

Development of the Adrenal Cortex, Adrenal Androgen Metabolism, and Factors Modulating Androgenic Effects

During prenatal life, the fetal zone (FZ) of the adrenal cortex secretes androgen precursors, mainly DHEA and DHEAS, for the placental estrogen production [reviewed in [24]]. During the first months after birth, the FZ regresses by apoptosis, and the secretion of AAPs decreases remaining low until adrenarche [25]. Thereafter, the androgen-producing ZR begins to develop from small focal islets. Adrenarche is a gradual process, and in some children AAPs are produced from early years [26,27]. By mid-childhood, a continuous ZR has usually been formed producing increasing but individually highly variable amounts of AAPs [reviewed in [5]].

The steroidogenic pathways in the ZR are presented in figure 1. All adrenal steroid hormones are synthesized from cholesterol which is converted to pregnenolone in the mitochondria by the cholesterol side-chain cleavage enzyme (P450scc, CYP11A1). The steroidogenic acute regulatory protein governs the acute response to adrenocorticotropic hormone (ACTH) by facilitating the movement of cholesterol from the outer to the inner mitochondrial membrane. The remaining enzymes needed for AAP synthesis in the ZR are 17-hydroxylase/17,20-lyase (P450c17, CYP17A1), 3β-hydroxysteroid dehydrogenase 2 (3βHSD2, HSD3B2), and sulfotransferase (SULT2A1). P450 oxidoreductase (POR) serves as an obligatory electron donor for P450c17, and cytochrome b5 acts as an allosteric factor promoting the 17,20-lyase reaction [reviewed in [18]].

Fig. 1

Steroidogenesis in the ZR of the human adrenal cortex (left panel) and peripheral conversion of AAPs DHEA and DHEAS prior to the final AR-mediated action in peripheral cells (right panel). The middle panel depicts the variably altered steroid pattern in the circulation of children with PA compared to that of age-matched control children [2,5]. (1) The expression and activity of the steroidogenic enzymes and their cofactors in ZR influence the adrenal androgen (precursor) secretion; high 17,20-lyase activity of the 17-hydroxylase/17,20-lyase enzyme (CYP17) and expression of POR and cytochrome b5 (b5) are essential [18]. (2) Possible minor T secretion from ZR [19], gonads or peripheral tissues may contribute to circulating T levels. (3) The expression and activity of the steroid-converting enzymes in peripheral tissues determine the formation of biologically active androgens from AAPs. (4) An alternative backdoor pathway to DHT formation [30]. (5) An alternative pathway from 11β-hydroxyandrostenedione (11OHA4) via 11β-hydroxytestosterone (11OHT) to a bioactive androgen 5α,11β-hydroxytestosterone (5,11OHT) [19]. (6) The activity of AR is influenced by AR gene polymorphisms, epigenetic modulations, and expression of its cofactors/comodulators [70,71,72]. A4 = Androstenedione; StAR = steroidogenic acute regulatory protein; 17OHPreg = 17OH-pregnenolone; 3βHSD = 3β-hydroxysteroid dehydrogenase (HSD3B); 17βHSD = 17β-hydroxysteroid dehydrogenase (HSD17B); ↑ = increased steroid concentration; ↔ = no reported change in the circulation of children with PA.

Fig. 1

Steroidogenesis in the ZR of the human adrenal cortex (left panel) and peripheral conversion of AAPs DHEA and DHEAS prior to the final AR-mediated action in peripheral cells (right panel). The middle panel depicts the variably altered steroid pattern in the circulation of children with PA compared to that of age-matched control children [2,5]. (1) The expression and activity of the steroidogenic enzymes and their cofactors in ZR influence the adrenal androgen (precursor) secretion; high 17,20-lyase activity of the 17-hydroxylase/17,20-lyase enzyme (CYP17) and expression of POR and cytochrome b5 (b5) are essential [18]. (2) Possible minor T secretion from ZR [19], gonads or peripheral tissues may contribute to circulating T levels. (3) The expression and activity of the steroid-converting enzymes in peripheral tissues determine the formation of biologically active androgens from AAPs. (4) An alternative backdoor pathway to DHT formation [30]. (5) An alternative pathway from 11β-hydroxyandrostenedione (11OHA4) via 11β-hydroxytestosterone (11OHT) to a bioactive androgen 5α,11β-hydroxytestosterone (5,11OHT) [19]. (6) The activity of AR is influenced by AR gene polymorphisms, epigenetic modulations, and expression of its cofactors/comodulators [70,71,72]. A4 = Androstenedione; StAR = steroidogenic acute regulatory protein; 17OHPreg = 17OH-pregnenolone; 3βHSD = 3β-hydroxysteroid dehydrogenase (HSD3B); 17βHSD = 17β-hydroxysteroid dehydrogenase (HSD17B); ↑ = increased steroid concentration; ↔ = no reported change in the circulation of children with PA.

Close modal

The AAPs DHEA and DHEAS are very weak androgen receptor (AR) agonists [18,19], and their concentrations do not straightforwardly correlate with the clinical androgenic signs [3]. In the light of current data, peripheral metabolism of AAPs is needed for the efficient AR activation and clinical androgenic action. This view is supported by our recent studies demonstrating low androgen bioactivity in serum samples of children with PA [28] and higher prevalence of clinical signs of androgen action in prepubertal girls than in boys with equal serum DHEAS concentrations [29]. The enzymes involved in the peripheral AAP metabolism include 3βHSD1 (HSD3B1), 17β-hydroxysteroid dehydrogenase 5 (17βHSD5, HSD17B5), and 5α-reductase (SRD5A). Dihydrotestosterone (DHT) can also be formed via the so-called alternative backdoor pathway which bypasses both androstenedione and testosterone (T) as intermediates [30] (fig. 1).

Regulation of AAP Secretion in Normal-Timed and Premature Adrenarche

Biochemical adrenarche, the reactivation of AAP production, is a gradual process [26,27]. The regulators of this physiologic process remain at least partly obscure. Pituitary ACTH is needed for adrenocortical androgen production, as evidenced e.g. by the lack of adrenarche in familial glucocorticoid deficiency due to ACTH receptor defects [31] and in children with hypopituitarism [32]. However, ACTH is probably not the trigger for adrenarche, and no other initiator has been identified [reviewed in [4], [5], [18], [19]]. While the initiating mechanisms of normal adrenarche remain unknown, several factors have been suggested to participate in the regulation of increased androgen production in PA, and this process may sometimes be a consequence of prenatal programming. The causes of (clinical) PA can basically act at two levels: (1) by activating the maturation of ZR and increasing AAP production, or (2) by enhancing peripheral conversion of AAPs to T and DHT, and/or by activating the AR.

Intrauterine growth retardation, being born small for gestational age, or even lower birth weight within the normal range are associated with increased serum DHEAS levels before puberty, especially if accompanied with rapid weight gain in early childhood [33,34]. A linkage between a history of low birth weight (LBW) and clinical PA has been shown in some [16,35,36] but not all studies [22,33,37,38]. Moreover, obesity (increased fat mass) has been associated with higher prepubertal AAP production also in children with normal birth weight [39,40]. Factors that have been suggested to mediate the effect of obesity on AAP production include insulin, IGF-1, and leptin [reviewed in [4], [5]]. Moreover, the conversion of AAPs to active androgens in peripheral adipose tissue may be enhanced by obesity [29].

Before the diagnosis of PA can be accepted, other causes of androgen excess should be ruled out. Differential diagnosis of PA should include defects of cortisol synthesis, most importantly late-onset congenital adrenal hyperplasia (LO-CAH) and even simple virilizing CAH especially in boys, adrenal or gonadal androgen-producing tumors, precocious puberty, and exposure to exogenous androgens [reviewed in [4], [5]].

Of the pathologic causes of prepubertal adrenal hyperandrogenism, LO-CAH due to 21-hydroxylase deficiency is the most common. Other enzymatic defects causing LO-CAH with hyperandrogenism include mutations in the genes encoding for 3βHSD2 (HSD3B2) [41] and 11β-hydroxylase (P450c11, CYP11B1) [42]. ‘True' cortisone reductase deficiency, inactivating mutations in the 11β-hydroxysteroid dehydrogenase 1 (11βHSD1, HSD11B1) gene, and apparent cortisone reductase deficiency due to inactivating mutations in the hexose-6-phosphate dehydrogenase (H6PDH) gene, cause ACTH-driven adrenal hyperandrogenism by reduced peripheral conversion of cortisone to cortisol [43]. A rare genetic reason in adrenal androgen metabolism leading to PP with high DHEA and biologically active androgens but low DHEAS, was recently explained by an inactivating mutation in the PAPSS2 gene encoding for a cofactor (PAPS synthase 2) needed in SULT2A1 enzymatic action [44].

The prevalence of CAH among PP patients varies substantially in different study populations (0-43% for all types of CAH) [3,41,45,46,47]. Some investigators suggest that LO-CAH can be excluded in PP subjects by the measurement of basal serum 17-OH-progesterone [48], while others suggest performing the ACTH test if CAH is suspected clinically [46,49,50]. A useful and accurate method for the differential diagnosis of steroidogenic enzyme defects is the analysis of urinary steroid metabolome in experienced hands [42,43].

Differential diagnosis between PA and LO-CAH (and the other mentioned genetic reasons for adrenal hyperandrogenism) is not always obvious based on clinical examination, but rapidly accelerating growth in height, remarkable androgenic signs and bone age advancement, and a positive family history are clues to a genetic disorder. Androgen-producing tumors are rare in children, but they should be considered if androgenic signs are severe (for example clitoromegaly in a girl or penile enlargement in a boy with a prepubertal testicle size) and/or growth velocity is markedly accelerated. Precocious central puberty can usually be diagnosed clinically: the Tanner stage for breast development ≥B2 in girls and testicular volume >3 ml in boys indicate ongoing puberty. However, in obese PA girls, budding breast development can sometimes occur owing to peripheral estrogen synthesis from AAPs without central puberty.

The prevalence of PA varies considerably depending on which criteria are used and which population is studied, with higher incidence in children of African-American ethnicity [51]. In a recent Finnish population-based study, the prevalence of PA (defined by serum DHEAS exceeding 1 μmol/l and any androgenic sign before the age of 8 years in girls and 9 years in boys) was 8.6% in girls and 1.8% in boys [29]. Several previous studies have also shown that PA is more common in girls than in boys [1,2,3,22,36].

The clinical signs of PA include oily hair and skin, adult-type body odor and the appearance of pubic and axillary hair [1,2,3,4,5]. The androgenic signs in PA often manifest in a typical order but with varying circulating androgen levels between patients. In our Finnish-Caucasian PA cohort, the first clinical sign of adrenarche was most often adult-type body odor, while pubarche and axillary hair were typically the last androgenic signs and present in only about half of the subjects at diagnosis. Serum DHEAS concentrations were higher in the PA subjects with pubic or axillary hair than in those with other signs only, forming a logic continuum [3]. DHEAS is considered the best marker of adrenal androgen secretion. Also other adrenal androgens (DHEA and androstenedione) may be increased for age. On the other hand, it is not uncommon that a child with signs typical for PA has a normal prepubertal serum DHEAS concentration [<1 µmol/l (≈40 µg/dl)] [3,5]. In follow-up studies of PA girls, the increase in serum AAP concentrations has been slow, their levels have usually remained appropriate for the pubic hair stage, and they have in most cases normalized for age by the end of puberty [1,37,52]. However, studies on Catalan PP girls have suggested that ovarian and adrenal hyperandrogenism may persist until postpuberty [15,53].

Children with PA are typically heavier than their peers [3,7,9,12,22,35,36]. Overweight may be accompanied by acanthosis nigricans [7,9]. Increased mean prepubertal height has been found in most described PA cohorts [2,6,38,52,54]. Our Finnish PA girls were 1.2 standard deviations scores taller than their prepubertal controls at the median age of 7.6 years. Most of this difference in height had been gained already by the age of 2 years [38]. An increased circulating IGF-1 level has also been found in several PA cohorts [38,55,56]. Bone age is often advanced in PA, usually appropriately for the enhancement of growth in height [2,56]. In a multi-ethnic study with prepubertal PA and control children, bone age advancement was most strongly associated with obesity, and to a smaller extent with estradiol and DHEAS levels [56]. It seems that children with PA use a greater part of their genetic growth potential before puberty compared with controls [52], while normal expected adult height is usually reached [23,52,54]. Menarche occurred about 0.5 years earlier in Finnish [52] and slightly less than 1 year earlier than expected in Spanish-Catalan PA girls [23].

Three studies have analyzed bone mineral density (BMD) in PA. In Catalan PP girls, BMD measures were higher than the respective population reference values [57]. An American study showed higher total body BMD in the PA than control girls at prepubertal age [58]. In our study including both girls and boys, BMD did not differ between the PA and control subjects when the size of the child was accounted for [59].

There are only few studies investigating psychological, social or cognitive effects of PA. One American study found lower scores on intelligence tests and more self-reported depression in PA girls compared with peers [60]. Another study found that girls with PA performed worse than controls on verbal, working memory, and visuospatial tasks [61].

An association between PA and increased prevalence of FOH was reported in 1993 in postpubertal Spanish-Catalan girls with a history of PP due to PA [14]. Soon thereafter, a group of girls with PP (due to PA) and acanthosis nigricans was shown to have decreased insulin sensitivity in a small multi-ethnic American cohort [7]. These two studies aroused interest in possible later harmful metabolic consequences of PA which had until then been considered a benign variant of pubertal development. Thereafter, several studies have found unfavorable metabolic features in PA subjects at the time of diagnosis or later during follow-up (table 1). Not all studies, however, have found a connection between PA and hyperinsulinism or other features of MBS.

Table 1

Main studies investigating components and markers of the metabolic syndrome in PA subjects

Main studies investigating components and markers of the metabolic syndrome in PA subjects
Main studies investigating components and markers of the metabolic syndrome in PA subjects

The most consistently reported component of MBS (insulin resistance/hyperinsulinism, central obesity, hypertension, dyslipidemia) in PA seems to be hyperinsulinism (table 1). However, in Brazilian girls with a history of PP (due to PA), no evidence of hyperinsulinism or insulin resistance was detected at the mean age of 12.1 years [62]. In most PA cohorts, PA has also been connected with overweight [7,9,12,22,35,36,56]. Interestingly, in the most extensively studied Catalan PA population, the girls with a history of PP were nonobese. However, they had an increased mean waist-to-hip ratio, total and abdominal fat mass and fat percentage compared to the control girls (n = 65) matched for age and pubertal breast stage. As the authors recognized, the interpretation of these findings needs some caution due to the height/weight differences of the study groups especially at the prepubertal and early pubertal stages [11]. In our Finnish population-based study, ‘childhood MBS' (defined using child-adjusted MBS criteria) was more common in the PA than control children (child-adjusted WHO criteria 16 vs. 5% and ATP III criteria 24 vs. 10%), mainly due to the higher prevalence of overweight in the PA group [12]. Also the circulating levels of some adipokines and inflammatory markers, including leptin, plasminogen activator inhibitor-1 and TNF-α, have been reported to be increased in PA subjects [13,57,63,64].

In Catalan girls with a history of PP due to PA, the prevalence of FOH was increased during and after puberty [14,15]. Especially the combination of LBW and hyperinsulinism was connected with subsequent development of FOH in postpubertal PP girls [16], thereby suggesting an extension to the hypothesis of the developmental origin of health and disease. On the other hand, a small American study on prepubertal PP (PA) girls did not show evidence of FOH [65]. In French-Caucasian postpubertal girls with a history of PP due to PA, the frequency of oligomenorrhea and insulin resistance parameters in oral glucose tolerance tests were similar to controls, and no connection between body weight and serum androgen levels was found [37]. On the basis of the observed inconsistencies in the frequency of FOH and polycystic ovarian morphology in subjects with a history of PA, additional follow-up studies on ovarian function from the diagnosis of PA until adulthood will be needed.

It is apparent that genetic factors contribute to adrenal androgen secretion and action, and thus also to the timing and strength of adrenarche. In a twin study, adrenal androgen excretion rate showed a heritability of 58% in prepubertal and pubertal subjects. Environmental factors accounted for 17% of the variation, and their role might be more important in girls than in boys [66]. Several studies have searched for susceptibility variants in genes involved in steroidogenesis, androgen action, insulin-IGF signaling, body weight regulation, and Wnt signaling. Already one of the first reports showed the presence of polymorphisms/mutations at several candidate loci, especially steroidogenic enzyme genes, in American children with PP and adolescent girls with hyperandrogenism [41]. Studies revealing statistically significant associations between genetic variation and PA are listed in table 2. Many of the studies had insufficient power to exclude the negative findings, and genome-wide association studies on adrenarche or adrenal androgen secretion during childhood and adolescence are missing.

Table 2

Candidate gene polymorphism studies showing association between the variants and premature adrenarche

Candidate gene polymorphism studies showing association between the variants and premature adrenarche
Candidate gene polymorphism studies showing association between the variants and premature adrenarche

Melanocortin type 2 receptor mediates the effects of ACTH on ZR, and a single nucleotide polymorphism (SNP) near the transcription initiation site of the gene encoding for this receptor has been associated with PA severity [67]. The genes encoding steroidogenic enzymes have been tempting candidates for the genetic regulation of PA. P450-aromatase (CYP19) encodes the aromatase enzyme that catalyzes the conversion of androgens to estrogens. The genotype distribution of SNP50 at the coding region of CYP19 is different in Catalan PP girls, in whom the major allele homozygosity is associated with higher serum T and DHEAS levels and decreased insulin sensitivity [68]. On the other hand, common polymorphisms at POR, SULT2A1 or 11βHSD1(HSD11B1) were not associated with PA in a Finnish Caucasian population, suggesting that they do not significantly contribute to PA [69]. Increased sensitivity of hair follicles to androgens has been postulated as a possible pathogenic mechanism for PA. The AR gene contains a polymorphic region with a variable number of CAG repeats (CAGn) encoding a polyglutamine tract, the length of which has an inverse relationship with the transcriptional activity of the AR. Mediterranean girls with PP and Finnish PA subjects had the mean CAGn about one repeat shorter than controls [70,71,72]. In the Finnish cohort, the lean PA subjects had shorter CAGn than the PA subjects with higher BMI or the lean control subjects, suggesting that more active AR may play a significant role especially in lean PA subject [72]. The minor variant G at SNP E1013E in IGF-1R has been associated with higher circulating IGF-1 levels, and the frequency of this minor variant was increased in American PA children [73].

The significance of adrenarche in human maturation has remained an enigma. Adrenarche is a separate event from gonadarche, the pubertal activation of the hypothalamo-pituitary-gonadal axis, and it is not needed for the initiation of central puberty. It has been speculated that an increase in the DHEAS level at around 7 years of age enables the prolonged development of the prefrontal cerebral cortex in humans. As a neuroprotective hormone, DHEAS could protect synaptic plasticity in metabolically active parts of the brain [74]. There is some evidence on the anabolic effects of adrenarche. As already mentioned, prepubertal children with PA are often taller than their peers, have advanced bone age and reduced pubertal growth spurt, indicating that they may use a greater part of their growth potential before puberty than those with on-time or late adrenarche [52]. This suggests indirectly that adrenal androgens play a role also in normal pubertal growth spurt. Adrenal androgens may also contribute to the accrual of BMD [57,58,59] and erythropoiesis [75].

When clinical signs of PA have been noted, a careful physical examination and analysis of the growth chart of the child should be performed. The diagnosis of PA is based on exclusion of other causes of prepubertal hyperandrogenism (fig. 2). After affirming the PA diagnosis, assuring the family of the usually benign nature of the androgenic signs is important.

Fig. 2

Management of children with PA. 17OHP = 17-hydroxyprogesterone; DM2 = type 2 diabetes mellitus; SD = standard deviation; OGTT = oral glucose tolerance test; WC = waist circumference.

Fig. 2

Management of children with PA. 17OHP = 17-hydroxyprogesterone; DM2 = type 2 diabetes mellitus; SD = standard deviation; OGTT = oral glucose tolerance test; WC = waist circumference.

Close modal

There are few recommendations for the management of PP or PA, but a Clinical Practice Committee Publication on PP was published in this journal in 2010 [49]. Special treatment is neither available nor required in PA. Usually, intensive follow-up is not needed either, especially when the androgenic signs are mild. Some PA girls may have an increased risk for developing obesity-related metabolic disturbances, including insulin resistance and FOH or polycystic ovarian syndrome (PCOS). This risk may be higher in girls with LBW. Therefore, glucose and insulin measurements have been suggested for PA children with a history of LBW or acanthosis nigricans [50]. Insulin sensitivity could also be assessed if the child is obese or has a family history of MBS or type 2 diabetes. The PA girls with the triad of LBW, pronounced hyperandrogenism with PP, and hyperinsulinism merit closer follow-up. Emphasis of the follow-up should be in maintaining or reaching normal weight by lifestyle modification including physical exercise and healthy diet (fig. 2). Early metformin treatment has been suggested for PP girls with LBW in order to prevent the development of hirsutism, androgen excess and other PCOS features [76]. In view of the shortage of data on the safety and effectiveness of long-term use of metformin or insulin sensitizers in children and adolescents, the use of these medications in children with PP is not recommended outside of clinical trials [49]. Otherwise, the indications for metformin and insulin-sensitizing treatment should be the same as for other children/adolescents with obesity, insulin resistance and type 2 diabetes.

Adrenarche offers a possibility to study the regulation and physiologic role of AAPs, which remain mostly unclear. As for the PA, the main question is whether it is a form of early adrenal maturation with transient mild metabolic changes, or the first sign of persistent hyperandrogenism. The current evidence for a firm linkage between PA and PCOS is insufficient, although it may be true in some PA girls. Differentiating this subgroup remains a clinical challenge. Pediatricians should be aware that most patients with PA have mild, slowly progressive signs of the androgen effect and uncompromised adult height with no need for special follow-up. The families of the PA children should be informed about the usually benign nature of the condition.

1.
Korth-Schutz S, Levine LS, New MI: Serum androgens in normal prepubertal and pubertal children and in children with precocious adrenarche. J Clin Endocrinol Metab 1976;42:117-124.
2.
Voutilainen R, Perheentupa J, Apter D: Benign premature adrenarche: clinical features and serum steroid levels. Acta Paediatr Scand 1983;72:707-711.
3.
Utriainen P, Voutilainen R, Jääskeläinen J: Continuum of phenotypes and sympathoadrenal function in premature adrenarche. Eur J Endocrinol 2009;160:657-665.
4.
Idkowiak J, Lavery GG, Dhir V, Barrett TG, Stewart PM, Krone N, Arlt W: Premature adrenarche: novel lessons from early onset androgen excess. Eur J Endocrinol 2011;165:189-207.
5.
Voutilainen R, Jääskeläinen J: Premature adrenarche: etiology, clinical findings, and consequences. J Steroid Biochem Mol Biol 2015;145C:226-236.
6.
Silverman S, Migeon C, Rosemberg E, Wilkins L: Precocious growth of sexual hair without other secondary sexual development: ‘premature pubarche' a constitutional variation of adolescence. Pediatrics 1952;10:426-432.
7.
Oppenheimer E, Linder B, DiMartino-Nardi J: Decreased insulin sensitivity in prepubertal girls with premature adrenarche and acanthosis nigricans. J Clin Endocrinol Metab 1995;80:614-618.
8.
Ibanez L, Potau N, Chacon P, Pascual C, Carrascosa A: Hyperinsulinaemia, dyslipaemia and cardiovascular risk in girls with a history of premature pubarche. Diabetologia 1998;41:1057-1063.
9.
Vuguin P, Linder B, Rosenfeld RG, Saenger P, DiMartino-Nardi J: The roles of insulin sensitivity, insulin-like growth factor I (IGF-I), and IGF-binding protein-1 and -3 in the hyperandrogenism of African-American and Caribbean Hispanic girls with premature adrenarche. J Clin Endocrinol Metab 1999;84:2037-2042.
10.
Denburg MR, Silfen ME, Manibo AM, Chin D, Levine LS, Ferin M, McMahon DJ, Go C, Oberfield SE: Insulin sensitivity and the insulin-like growth factor system in prepubertal boys with premature adrenarche. J Clin Endocrinol Metab 2002;87:5604-5609.
11.
Ibanez L, Ong K, de Zegher F, Marcos MV, del Rio L, Dunger DB: Fat distribution in non-obese girls with and without precocious pubarche: central adiposity related to insulinaemia and androgenaemia from prepuberty to postmenarche. Clin Endocrinol 2003;58:372-379.
12.
Utriainen P, Jääskeläinen J, Romppanen J, Voutilainen R: Childhood metabolic syndrome and its components in premature adrenarche. J Clin Endocrinol Metab 2007;92:4282-4285.
13.
Mathew RP, Byrne DW, Linton MF, Vaughan DE, Fazio S, Russell WE: Evidence of metabolic syndrome in lean children with premature pubarche at diagnosis. Metabolism 2008;57:733-740.
14.
Ibáñez L, Potau N, Virdis R, Zampolli M, Terzi C, Gussinye M, Carrascosa A, Vicens-Calvet E: Postpubertal outcome in girls diagnosed of premature pubarche during childhood: increased frequency of functional ovarian hyperandrogenism. J Clin Endocrinol Metab 1993;76:1599-1603.
15.
Ibáñez L, Potau N, Zampolli M, Street ME, Carrascosa A: Girls diagnosed with premature pubarche show an exaggerated ovarian androgen synthesis from the early stages of puberty: evidence from gonadotropin-releasing hormone agonist testing. Fertil Steril 1997;67:849-855.
16.
Ibáñez L, Potau N, Francois I, de Zegher F: Precocious pubarche, hyperinsulinism, and ovarian hyperandrogenism in girls: relation to reduced fetal growth. J Clin Endocrinol Metab 1998;83:3558-3562.
17.
Belgorosky A, Baquedano MS, Guercio G, Rivarola MA: Adrenarche: postnatal adrenal zonation and hormonal and metabolic regulation. Horm Res 2008;70:257-267.
18.
Miller WL: Androgen synthesis in adrenarche. Rev Endocr Metab Disord 2009;10:3-17.
19.
Rege J, Rainey WE: The steroid metabolome of adrenarche. J Endocrinol 2012;214:133-143.
20.
Likitmaskul S, Cowell CT, Donaghue K, Kreutzmann DJ, Howard NJ, Blades B, Silink M: ‘Exaggerated adrenarche' in children presenting with premature adrenarche. Clin Endocrinol 1995;42:265-272.
21.
Ibanez L, Potau N, Marcos MV, de Zegher F: Exaggerated adrenarche and hyperinsulinism in adolescent girls born small for gestational age. J Clin Endocrinol Metab 1999;84:4739-4741.
22.
Paterson WF, Ahmed SF, Bath L, Donaldson MD, Fleming R, Greene SA, Hunter I, Kelnar CJ, Mayo A, Schulga JS, Shapiro D, Smail PJ, Wallace AM: Exaggerated adrenarche in a cohort of Scottish children: clinical features and biochemistry. Clin Endocrinol 2010;72:496-501.
23.
Ibanez L, Jimenez R, de Zegher F: Early puberty-menarche after precocious pubarche: relation to prenatal growth. Pediatrics 2006;117:117-121.
24.
Mesiano S, Jaffe RB: Developmental and functional biology of the primate fetal adrenal cortex. Endocr Rev 1997;18:378-403.
25.
Spencer SJ, Mesiano S, Lee JY, Jaffe RB: Proliferation and apoptosis in the human adrenal cortex during the fetal and perinatal periods: implications for growth and remodeling. J Clin Endocrinol Metab 1999;84:1110-1115.
26.
Palmert MR, Hayden DL, Mansfield MJ, Crigler JF Jr, Crowley WF Jr, Chandler DW, Boepple PA: The longitudinal study of adrenal maturation during gonadal suppression: evidence that adrenarche is a gradual process. J Clin Endocrinol Metab 2001;86:4536-4542.
27.
Remer T, Boye KR, Hartmann MF, Wudy SA: Urinary markers of adrenarche: reference values in healthy subjects, aged 3-18 years. J Clin Endocrinol Metab 2005;90:2015-2021.
28.
Liimatta J, Laakso S, Utriainen P, Voutilainen R, Palvimo JJ, Jääskeläinen T, Jääskeläinen J: Serum androgen bioactivity is low in children with premature adrenarche. Pediatr Res 2014;75:645-650.
29.
Mäntyselkä A, Jääskeläinen J, Lindi V, Viitasalo A, Tompuri T, Voutilainen R, Lakka TA: The presentation of adrenarche is sexually dimorphic and modified by body adiposity. J Clin Endocrinol Metab 2014;99:3889-3894.
30.
Kamrath C, Hochberg Z, Hartmann MF, Remer T, Wudy SA: Increased activation of the alternative ‘backdoor' pathway in patients with 21-hydroxylase deficiency: evidence from urinary steroid hormone analysis. J Clin Endocrinol Metab 2012;97:E367-E375.
31.
Weber A, Clark AJL, Perry LA, Honour JW, Savage MO: Diminished adrenal androgen secretion in familial glucocorticoid deficiency implicates a significant role for ACTH in the induction of adrenarche. Clin Endocrinol 1997;46:431-437.
32.
Boettcher C, Hartman MF, de Laffolie J, Zimmer KP, Wudy SA: Absent adrenarche in children with hypopituitarism: a study based on urinary steroid metabolomics. Horm Res Paediatr 2013;79:356-360.
33.
Tenhola S, Martikainen A, Rahiala E, Parviainen M, Halonen P, Voutilainen R: Increased adrenocortical and adrenomedullary hormonal activity in 12-year-old children born small for gestational age. J Pediatr 2002;141:477-482.
34.
Ong KK, Potau N, Petry CJ, Jones R, Ness AR, Honour JW, de Zegher F, Ibáñez L, Dunger DB; Avon Longitudinal Study of Parents and Children Study Team: Opposing influences of prenatal and postnatal weight gain on adrenarche in normal boys and girls. J Clin Endocrinol Metab 2004;89:2647-2651.
35.
Neville KA, Walker JL: Precocious pubarche is associated with SGA, prematurity, weight gain, and obesity. Arch Dis Child 2005;90:258-261.
36.
Charkaluk M-L, Trivin C, Brauner R: Premature pubarche as an indicator of how body weight influences the onset of adrenarche. Eur J Pediatr 2004;163:89-93.
37.
Meas T, Chevenne D, Thibaud E, Leger J, Cabrol S, Czernichow P, Levy-Marchal C: Endocrine consequences of premature pubarche in post-pubertal Caucasian girls. Clin Endocrinol 2002;57:101-106.
38.
Utriainen P, Voutilainen R, Jääskeläinen J: Girls with premature adrenarche have accelerated early childhood growth. J Pediatr 2009;154:882-887.
39.
Reinehr T, de Sousa G, Roth CL, Andler W: Androgens before and after weight loss in obese children. J Clin Endocrinol Metab 2005;90:5588-5595.
40.
Shi L, Wudy SA, Buyken AE, Hartmann MF, Remer T: Body fat and animal protein intakes are associated with adrenal androgen secretion in children. Am J Clin Nutr 2009;90:1321-1328.
41.
Witchel SF, Smith R, Tomboc M, Aston CE: Candidate gene analysis in premature pubarche and adolescent hyperandrogenism. Fertil Steril 2001;75:724-730.
42.
Reisch N, Högler W, Parajes S, Rose IT, Dhir V, Götzinger J, Arlt W, Krone N: A diagnosis not to be missed: nonclassic steroid 11β-hydroxylase deficiency presenting with premature adrenarche and hirsutism. J Clin Endocrinol Metab 2013;98:E1620-E1625.
43.
Lavery GG, Idkowiak J, Sherlock M, Bujalska I, Ride JP, Saqib K, Hartmann MF, Hughes B, Wudy SA, De Schepper J, Arlt W, Krone N, Shackleton CH, Walker EA, Stewart PM: Novel H6PDH mutations in two girls with premature adrenarche: ‘apparent' and ‘true' CRD can be differentiated by urinary steroid profiling. Eur J Endocrinol 2013;168:K19-K26.
44.
Noordam C, Dhir V, McNelis JC, Schlereth F, Hanley NA, Krone N, Smeitink JA, Smeets R, Sweep FC, Claahsen-van der Grinten HL, Arlt W: Inactivating PAPSS2 mutations in a patient with premature pubarche. N Engl J Med 2009;360:2310-2318.
45.
Temeck JW, Pang SY, Nelson C, New MI: Genetic defects of steroidogenesis in premature pubarche. J Clin Endocrinol Metab 1987;64:609-617.
46.
Siegel SF, Finegold DN, Urban MD, McVie R, Lee PA: Premature pubarche: etiological heterogeneity. J Clin Endocrinol Metab 1992;74:239-247.
47.
Balducci R, Boscherini B, Mangiantini A, Morellini M, Toscano V: Isolated precocious pubarche: an approach. J Clin Endocrinol Metab 1994;79:582-589.
48.
Armengaud JB, Charkaluk ML, Trivin C, Tardy V, Bréart G, Brauner R, Chalumeau M: Precocious pubarche: distinguishing late-onset congenital adrenal hyperplasia from premature adrenarche. J Clin Endocrinol Metab 2009;94:2835-2840.
49.
Ghizzoni L, Gasco V: Premature pubarche. Horm Res Paediatr 2010;73:420-422.
50.
Williams RM, Ward CE, Hughes IA: Premature adrenarche. Arch Dis Child 2012;97:250-254.
51.
Rosenfield RL, Lipton RB, Drum ML: Thelarche, pubarche, and menarche attainment in children with normal and elevated body mass index. Pediatrics 2009;123:84-88.
52.
Pere A, Perheentupa J, Peter M, Voutilainen R: Follow up of growth and steroids in premature adrenarche. Eur J Pediatr 1995;154:346-352.
53.
Ibáñez L, Potau N, Marcos MV, De Zegher F: Adrenal hyperandrogenism in adolescent girls with a history of low birthweight and precocious pubarche. Clin Endocrinol 2000;53:523-527.
54.
Ibáñez L, Virdis R, Potau N, Zampolli M, Ghizzoni L, Albisu MA, Carrascosa A, Bernasconi S, Vicens-Calvet E: Natural history of premature pubarche: an auxological study. J Clin Endocrinol Metab 1992;74:254-257.
55.
Silfen ME, Manibo AM, Ferin M, McMahon DJ, Levine LS, Oberfield SE: Elevated free IGF-I levels in prepubertal Hispanic girls with premature adrenarche: relationship with hyperandrogenism and insulin sensitivity. J Clin Endocrinol Metab 2002;87:398-403.
56.
Sopher AB, Jean AM, Zwany SK, Winston DM, Pomeranz CB, Bell JJ, McMahon DJ, Hassoun A, Fennoy I, Oberfield SE: Bone age advancement in prepubertal children with obesity and premature adrenarche: possible potentiating factors. Obesity (Silver Spring) 2011;19:1259-1264.
57.
Ibáñez L, Potau N, Ong K, Dunger DB, De Zegher F: Increased bone mineral density and serum leptin in non-obese girls with precocious pubarche: relation to low birthweight and hyperinsulinism. Horm Res 2000;54:192-197.
58.
Sopher AB, Thornton JC, Silfen ME, Manibo A, Oberfield SE, Wang J, Pierson RN Jr, Levine LS, Horlick M: Prepubertal girls with premature adrenarche have greater bone mineral content and density than controls. J Clin Endocrinol Metab 2001;86:5269-5272.
59.
Utriainen P, Jääskeläinen J, Saarinen A, Vanninen E, Mäkitie O, Voutilainen R: Body composition and bone mineral density in children with premature adrenarche and the association of LRP5 gene polymorphisms with bone mineral density. J Clin Endocrinol Metab 2009;94:4144-4151.
60.
Dorn LD, Hitt SF, Rotenstein D: Biopsychological and cognitive differences in children with premature vs. on-time adrenarche. Arch Pediatr Adolesc Med 1999;153:137-146.
61.
Tissot A, Dorn LD, Rotenstein D, Rose SR, Sontag-Padilla LM, Jillard CL, Witchel SF, Berga SL, Loucks TL, Beers SR: Neuropsychological functioning in girls with premature adrenarche. J Int Neuropsychol Soc 2012;18:151-156.
62.
de Ferran K, Paiva IA, Garcia Ldos S, Gama Mde P, Guimarães MM: Isolated premature pubarche: report of anthropometric and metabolic profile of a Brazilian cohort of girls. Horm Res Paediatr 2011;75:367-373.
63.
Ibáñez L, Aulesa C, Potau N, Ong K, Dunger DB, de Zegher F: Plasminogen activator inhibitor-1 in girls with precocious pubarche: a premenarcheal marker for polycystic ovary syndrome? Pediatr Res 2002;51:244-248.
64.
Utriainen P, Jääskeläinen J, Gröhn O, Kuusisto J, Pulkki K, Voutilainen R: Circulating TNF-alpha and IL-6 concentrations and TNF-alpha -308 G>A polymorphism in children with premature adrenarche. Front Endocrinol (Lausanne) 2010;1:6.
65.
Mathew RP, Najjar JL, Lorenz RA, Mayes DE, Russell WE: Premature pubarche in girls is associated with functional adrenal but not ovarian hyperandrogenism. J Pediatr 2002;141:91-98.
66.
Pratt JH, Manatunga AK, Li W: Familial influences on the adrenal androgen excretion rate during the adrenarche. Metabolism 1994;43:186-189.
67.
Lappalainen S, Utriainen P, Kuulasmaa T, Voutilainen R, Jääskeläinen J: ACTH receptor promoter polymorphism associates with the severity of premature adrenarche and modulates hypothalamo-pituitary-adrenal axis in children. Pediatr Res 2008;63:410-414.
68.
Petry CJ, Ong KK, Michelmore KF, Artigas S, Wingate DL, Balen AH, de Zegher F, Ibáñez L, Dunger DB: Association of aromatase (CYP 19) gene variation with features of hyperandrogenism in two populations of young women. Hum Reprod 2005;20:1837-1843.
69.
Utriainen P, Laakso S, Jääskeläinen J, Voutilainen R: Polymorphism of POR, SULT2A1 and HSD11B1 in children with premature adrenarche. Metabolism 2012;61:1215-1219.
70.
Ibáñez L, Ong K, Mongan N, Jääskeläinen J, Marcos MV, Hughes IA, De Zegher F, Dunger DB: Androgen receptor gene CAG repeat polymorphism in the development of ovarian hyperandrogenism. J Clin Endocrinol Metab 2003;88:3333-3338.
71.
Vottero A, Capelletti M, Giuliodori S, Viani I, Ziveri M, Neri TM, Bernasconi S, Ghizzoni L: Decreased androgen receptor gene methylation in premature pubarche: a novel pathogenetic mechanism? J Clin Endocrinol Metab 2006;91:968-972.
72.
Lappalainen S, Utriainen P, Kuulasmaa T, Voutilainen R, Jääskeläinen J: Androgen receptor gene CAG repeat polymorphism and X-chromosome inactivation in children with premature adrenarche. J Clin Endocrinol Metab 2008;93:1304-1309.
73.
Roldan MB, White C, Witchel SF: Association of the GAA1013->GAG polymorphism of the insulin-like growth factor-1 receptor (IGF1R) gene with premature pubarche. Fertil Steril 2007;88:410-417.
74.
Campbell BC: Adrenarche and middle childhood. Hum Nat 2011;22:327-349.
75.
Utriainen P, Jääskeläinen J, Voutilainen R: Blood erythrocyte and hemoglobin concentrations in premature adrenarche. J Clin Endocrinol Metab 2013;98:E87-E91.
76.
Ibáñez L, Lopez-Bermejo A, Diaz M, Marcos MV, de Zegher F: Early metformin therapy (age 8-12 years) in girls with precocious pubarche to reduce hirsutism, androgen excess, and oligomenorrhea in adolescence. J Clin Endocrinol Metab 2011;96:E1262-E1267.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.